Joshua, A. M., Ameratunga, M., Serrano, A., Lay, A., Kent, R., Psaroulis, T., Reale, A., Kalsi, M. S., Laplap, C., Cosman, R., Shackleton, M. J. (2026). SILVER (supplementing tebentafusp with subcutaneous IL-2 to verifiably eradicate radiological progression): A phase 1/2 trial of IL-2 with tebentafusp upon first radiological progression on first-line tebentafusp alone.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps9606